Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WNT1 | P04628 | 8/20 | 0.65 |
| ▸ | TGFBR1 | P36897 | 7/20 | 0.65 |
| ▸ | CLK2 | P49760 | 12/20 | 0.62 |
| ▸ | CLK3 | P49761 | 12/20 | 0.62 |
| ▸ | DYRK1A | Q13627 | 12/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18449040 | 0.91 | CLK2 (0.64) | WNT1TGFBR1CLK2CLK3DYRK1A | |
| SCHEMBL17588689 | 0.91 | DYRK1A (0.62) | WNT1TGFBR1CLK2CLK3DYRK1A | |
| SCHEMBL17566858 | 0.90 | WNT1 (0.80) | WNT1TGFBR1CLK2CLK3DYRK1A | |
| SCHEMBL17575779 | 0.90 | WNT1 (0.68) | WNT1TGFBR1CLK2CLK3DYRK1A | |
| SCHEMBL17568489 | 0.90 | WNT1 (0.67) | WNT1TGFBR1CLK2CLK3DYRK1A | |
| SCHEMBL17568496 | 0.89 | WNT1 (0.61) | WNT1TGFBR1CLK2CLK3DYRK1A | |
| SCHEMBL17568505 | 0.89 | WNT1 (0.63) | WNT1TGFBR1CLK2CLK3DYRK1A | |
| SCHEMBL17568522 | 0.89 | WNT1 (0.63) | WNT1TGFBR1CLK2CLK3DYRK1A | |
| SCHEMBL17567747 | 0.89 | CLK2 (0.79) | WNT1TGFBR1CLK2CLK3DYRK1A | |
| SCHEMBL17568512 | 0.89 | CLK2 (0.78) | WNT1TGFBR1CLK2CLK3DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9844536-B2 | 3-(1H-imidazo[4,5-C]pyridin-2-yl)-1H-pyrazolo[3,4-C]pyridine and therapeutic uses thereof | SAMUMED, LLC (US) | 2017-12-19 | — | — | US | disclosed |
| US-9844536-B2 | 3-(1H-imidazo[4,5-C]pyridin-2-yl)-1H-pyrazolo[3,4-C]pyridine and therapeutic uses thereof | SAMUMED, LLC (US) | 2017-12-19 | — | — | US | disclosed |
| US-20170267697-A1 | 3-(1H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINE AND THERAPEUTIC USES THEREOF | VICKERS-SPLICE CO-INVESTMENT LLC (KY) | 2017-09-21 | — | — | US | disclosed |
| US-20170267697-A1 | 3-(1H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINE AND THERAPEUTIC USES THEREOF | VICKERS-SPLICE CO-INVESTMENT LLC (KY) | 2017-09-21 | — | — | US | disclosed |
| US-9540398-B2 | 3-(1h-imidazo[4,5-C]pyridin-2-yl)-1h-pyrazolo[3,4-C]pyridine and therapeutic uses thereof | SAMUMED, LLC (US) | 2017-01-10 | — | — | US | disclosed |
| US-9540398-B2 | 3-(1h-imidazo[4,5-C]pyridin-2-yl)-1h-pyrazolo[3,4-C]pyridine and therapeutic uses thereof | SAMUMED, LLC (US) | 2017-01-10 | — | — | US | disclosed |
| US-20160068547-A1 | 3-(1H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINE AND THERAPEUTIC USES THEREOF | VICKERS VENTURE FUND VI (PLAN) PTE. LTD. (SG) | 2016-03-10 | — | — | US | disclosed |
| US-20160068547-A1 | 3-(1H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINE AND THERAPEUTIC USES THEREOF | VICKERS VENTURE FUND VI (PLAN) PTE. LTD. (SG) | 2016-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160068547-A1 | 3-(1H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINE AND THERAPEUTIC USES THEREOF | WNT1, WNT3, WNT3A | WNT1 1/4885TGFBR1 479/4885CLK2 2251/4885 |
| US-20170267697-A1 | 3-(1H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINE AND THERAPEUTIC USES THEREOF | WNT1, WNT3, WNT3A | WNT1 1/4885TGFBR1 479/4885CLK2 2251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.